Applied UV, Inc. · OTC:AUVI
Applied UV — IPO Roadshow (July 2020)
19 slides from Applied UV's IPO roadshow presentation, Jul 28, 2020
Slide 1: Applied UV, Inc. Investor Presentation July 2020
Applied UV, Inc . Patent - protected Devices Addressing Global Healthcare Pathogen Crisis, Combining New IP with a Profitable Business having Approximately $10 Million in Revenue Applied UV, Inc. Investor Presentation July 2020 Free Writing Prospectus filed pursuant to Rule 433 Registration Statemen
Slide 2: Safe Harbor Statement
Applied UV, Inc. > This presentation may contain “forward - looking statements . ” Forward - looking statements reflect the current view about future events . When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these t
Slide 3: Free Writing Prospectus Status
Applied UV, Inc. > This presentation highlights basic information about our company . Because it is a summary, it does not contain all of the information that you should consider before investing . This offering may only be made by means of a prospectus . We have filed a registration statement (incl
Slide 4: Why was Applied UV formed?
Applied UV, Inc. > 4 Why was Applied UV formed? Foundation Hospitality mirrors for the world’s finest hotels Expansion Solve a critical problem in – Hospital Acquired Infections (HAI) Opportunity Address the biggest issue of our lifetime • Munn Works was formed in 2012, growing 15% per year with 201
Slide 5: Applied UV: Two Synergistic Subsidiaries
> Applied UV, Inc. 5 Applied UV: Two Synergistic Subsidiaries • Patent protected technology for killing pathogens on surfaces, across global market segments such as healthcare, hospitality, and public sector (e.g. schools) • Kills pathogens on surfaces in a highly effective and affordable manner • T
Slide 6: Munn Works: A Strong Foundation
Applied UV, Inc. > o A global manufacturer of fine mirrors, designed to fit every type of hotel interior from modern to antique o Domestic and overseas manufacturing and distribution o Expansion: Synergistic acquisitions (i.e. hotel lighting) o Continuing business from high - end chains and hospital
Slide 7: SteriLumen: Solving the 'Hospital Acquired Infections' Problem
Applied UV, Inc. > Problem: HAI’s kill 99 thousand & infect 1.4 million hospital patients a year o The #1 areas where pathogens live in a hospital room are sinks and drains: o More pathogen - concentration than toilet 1 o Spread of MRSA, e - coli, c - diff, OC43 Human Coronavirus, new antibiotic - r
Slide 8: SteriLumen: Affordable and Effective Pathogen Destruction
Applied UV, Inc. > 8 SteriLumen: Affordable and Effective Pathogen Destruction Problem: COVID - 19 (Coronavirus) impacts are far beyond the hospital, touching every market and industry Solution: SteriLumen technology kills pathogens, including OC43 human coronavirus on surfaces 1 o Pathogen destruct
Slide 9: Testing against OC43 human coronavirus
Applied UV, Inc. > o In accordance with CDC guidelines, a bio safety level 3 laboratory is required for testing SARS - CoV - 2, the virus that causes COVID - 19 o There are a limited number of bio safety level (“BSL”) 3 laboratories available due to the high demand for COVID - 19 testing for vaccine
Slide 10: No Good Alternatives in Market
Applied UV, Inc. > 10 No Good Alternatives in Market Performed at best every 24 hours, allowing for the possibility of recontamination Manual Disinfection UV Room Devices/Robots Hydrogen Peroxide Vapor SteriLumen Can run as needed Manpower intensive (hospitals, hotels) Expensive (~$2.5K - $70K/ unit
Slide 11: SteriLumen: Patent Protected
Applied UV, Inc. > 11 SteriLumen: Patent Protected As of June 30, 2020, SteriLumen owns six issued patents and one pending patent application in the United States. The pending application will be issuing as a patent on August 11, 2020. A patent application is in the process of being filed for system
Slide 12: SteriLumen: Testing, Validation & Trademark
Applied UV, Inc. > Testing: o Independent testing laboratory, ResInnova Laboratories, determined that the Sterilumen Disinfecting System to be effective up to 4.56 logs (99.9956%) in reducing pathogens, including the coronavirus on surfaces in the bathroom vanity/sink area (including C - Diff, E.col
Slide 13: Market Verticals & Pipeline
Applied UV, Inc. > 13 Market Verticals & Pipeline Key Market Segments Key Metrics Healthcare/ Hospitals • HAI’s cause 99,000 Deaths/Year in US (CDC) 1 • Costs Hospitals approximately $37B/Year in US alone 2 Hospitality • Hotels currently on pace to lose up to $400M/Day in room revenue 3 Retail • Foo
Slide 14: Experienced Management Team
> Applied UV, Inc. 14 Experienced Management Team Keyoumars (Q) Saeed Chief Executive officer and Director Max Munn President MunnWorks / Founder and Director Jim Doyle Chief Operating Officer Joseph Himy Chief Financial Officer • CEO Ubiquity LLC • CEO & Founder at Vital Neuro, Inc. • CSO at Kymeta
Slide 15: Strong Independent Board Leadership and Capability
> Applied UV, Inc. 15 Strong Independent Board Leadership and Capability Joel Kanter Chairman of the Board Dr. Eugene A. Bauer, M.D. Director Alastair J. Clemow , Ph.D. Director Dallas C. Hack, M.D., Colonel US Army (Retired) Director Eugene E. Burleson Director • President, Windy City Inc. • CEO Wa
Slide 16: Go to Market Strategy
Applied UV, Inc. > o Complete institutional validation with Mt. Sinai and other key influencers o Drive initial pipeline and sales with visible, high value launch customers o Attack key verticals: o Hospitality: Hotels, Casinos, etc. (Leverage MunnWorks) o Entertainment & Leisure: Travel Cruise line
Slide 17: Financial Summary
Applied UV, Inc. > 17 Financial Summary 1,2 1 All net sales for 2019 and 2018 were generated entirely from Munn Works LLC. 2 For more details see the Company’s audited and interim financial statements in the Company’s Registration Statement on Form S - 1, filed on [*], 2020 . 2019 2018 Net Sales $ 9
Slide 18: Offering Summary
Applied UV, Inc. > 18 Offering Summary Issuer: Applied UV, Inc. Securities Offered : Common Stock Offering Type: Initial Public Offering (IPO) Exchange Symbol : NASDAQ: AUVI Pre - Offering Shares Outstanding: 5,154,350 Number of Shares Offered: 1,000,000 Post - Offering Shares Outstanding : 6,186,85
Slide 19: Company Contact
Applied UV, Inc. Company Contact: Applied UV, Inc. 150 North Macquesten Pkwy Mount Vernon, NY 10550 914.665.6100 Q Saeed, CEO q@sterilumen.com www.applieduv.com www.munnworks.com www.sterilumen.com Underwriter Contact: Network1 Financial Securities, Inc. 2 Bridge Avenue, Suite 241 Red Bank, NJ 07701